Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC reduced its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 3.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,280 shares of the company’s stock after selling 814 shares during the quarter. MetLife Investment Management LLC’s holdings in Omnicell were worth $1,146,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Victory Capital Management Inc. boosted its position in shares of Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after buying an additional 909,480 shares during the period. Sumitomo Mitsui Trust Group Inc. acquired a new position in Omnicell in the third quarter valued at $32,721,000. Pacer Advisors Inc. boosted its holdings in Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after acquiring an additional 508,789 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Omnicell by 750.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after acquiring an additional 259,463 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Down 0.1 %

Shares of OMCL stock opened at $46.00 on Friday. The firm has a fifty day simple moving average of $44.90 and a 200-day simple moving average of $38.49. The company has a market capitalization of $2.13 billion, a PE ratio of -117.95, a price-to-earnings-growth ratio of 35.64 and a beta of 0.77. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.74.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on OMCL shares. JPMorgan Chase & Co. lifted their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Bank of America reaffirmed a “neutral” rating and set a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Craig Hallum increased their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, Wells Fargo & Company increased their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus target price of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.